ASX Announcement **20 November 2026**

BlinkLab Presents Digital Biomarker Data in Autism and ADHD at Neuroscience 2026, the World's Largest Neuroscience Conference

Highlights

- **Two data presentations at Neuroscience 2026:** BlinkLab and its academic collaborators presented their autism and ADHD data at the annual meeting of the Society for Neuroscience, held in Washington, D.C. from 14 to 18 November 2026.
- **Building awareness among scientists and clinicians:** Neuroscience 2026 is the world's largest annual neuroscience meeting organized by the Society for Neuroscience, drawing more than 30,000 attendees. Presenting there, builds awareness of BlinkLab's products in the scientific and clinical community, which supports future clinical adoption and partnerships.
- **Objective digital biomarkers for autism:** The autism presentation, collected in collaboration with Mohammed V Foundation for Solidarity in Morocco, showed how reflex-based and spontaneous sensorimotor biomarkers can be combined to distinguish autistic from neurotypical children. This supports the scientific basis of BlinkLab's autism diagnostic program.
- **Objective symptom measurement in ADHD:** The ADHD presentation, collected with Mental Care Group in The Netherlands, showed that smartphone-derived movement biomarkers were correlated with clinician-rated hyperactivity and impulsivity. This points to an objective way to measure symptom severity in a condition still assessed by rating scales.
- **Dx1 regulatory program remains unchanged:** The U.S. pivotal study of BlinkLab Dx1 remains the Company's priority, with submission to the U.S. Food and Drug Administration (FDA) expected in Q1 2027.

BlinkLab Limited (ASX:BB1) ("BlinkLab" or the "Company") is pleased to announce that recent clinical data from its autism and ADHD research programs were presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN), held in Washington, D.C. from 14 to 18 November 2026.

Why Society for Neuroscience Matters

The Society for Neuroscience has over 30,000 members in more than 95 countries, and its annual meeting regularly draws more than 30,000 attendees from about 80 countries[1]. Presenting at this meeting places BlinkLab's data before the clinical and scientific community that will shape adoption of digital biomarkers, and before the academic and industry groups that could become research and commercial partners.

Data Presented at the Neuroscience Conference

The first presentation was on objective digital biomarkers for autism, showing how reflex-based and spontaneous sensorimotor biomarkers, captured in a 15-minute smartphone assessment, can be combined to distinguish autistic from neurotypical children. The title is *"Multivariate Neurobehavioral Measures as Objective Markers of Autism"* and is presented by Kayleigh Gultig (MSc and PhD student), Clinical Research Associate at BlinkLab. The cohort is the one reported in the Company's peer-reviewed paper in *Autism Research* (2026)[2].

The second presentation was on smartphone-derived movement markers that were correlated with clinician-rated ADHD symptoms, including hyperactivity, impulsivity, and inattention. *"Characterizing Sensory Processing in Children with ADHD Using Smartphone-Based Measurements of Acoustic Startle and Prepulse Inhibition"* and is presented by Lotte Roggeveen (MSc), Clinical Research Manager at BlinkLab[3].

A Research Engine Behind the Device

The data presented reflect how BlinkLab develops its technology.

- **Scale:** More than 600 children were assessed across Morocco and the Netherlands, in clinical and community settings.
- **Collaborations:** The work was conducted in collaboration with Erasmus MC, Princeton University, Mental Care Group, and the Mohammed V Foundation for Solidarity.
- **In-house science:** BlinkLab researchers are authors on both presentations, combining neuroscience, computer vision and machine learning in one team.

Potential Outcomes

This research can lead to a few important outcomes. First, this could enable earlier and faster autism assessment: an objective, biomarker-based aid that runs on a smartphone could support clinicians outside specialist centres and shorten the path to diagnosis. Second, objective ADHD monitoring: movement biomarkers that correlate with clinician ratings could be used to follow symptom severity over time and to measure response to treatment. Third, digital endpoints for drug development: pharmaceutical companies need repeatable, objective endpoints for neurodevelopmental trials, where outcomes still rely on rating scales. Finally, a much broader platform: the same reflex and

[1] Society for Neuroscience, About SfN (www.sfn.org/About)

[2] Gultig et al. (2026), Neurobehavioral assessment of sensorimotor function in autism using smartphone technology, Autism Research 19:e70166

movement biomarkers can be studied in other neurodevelopmental and psychiatric conditions. Each of these applications requires further clinical studies and, for clinical use, regulatory clearance.

This announcement has been authorised for release by the Board of BlinkLab Limited.

For further information please contact:

Dr Henk-Jan Boele
Managing Director & CEO
henkjan@blinklab.org
M: +31 (0) 611 132 247

Brian Leedman
Non-Executive Chairman
brian@blinklab.org
M: +61 (0) 412 281 780

About BlinkLab Limited

BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.

[3] ASX Announcement from 5 August 2026 "European ADHD Study Delivers Positive Results, Supporting Expansion of Diagnostic Platform Beyond Autism"